venerdì, 30 luglio 2021
Medinews
25 Maggio 2017

FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers

May 23, 2017 – The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine … (leggi tutto)

TORNA INDIETRO